This Thanksgiving, with so many families unable or unwilling (often smartly), to get together during the holiday, such a historically lazy and obvious answer has been suddenly endowed with real meaning.
Yes, even after that Pfizer thing. And neither are any of those cruise or airplane stocks. While the week began as the long-awaited rotation out of stay-at-home tech and into the beaten-down travel sector, the rotation already came and went. It lasted a whole day, long enough to sell those cruise stocks on the pop—I did.
Health insurer UnitedHealth Group (NYSE: UNH) rose 10%, while Cigna Corp (NYSE: CI) andAnthem Inc (NYSE: ANTM) jumped by double digits. These three stocks are solid buys for broad-sector exposure. But there is no healthcare company more perfectly positioned to benefit for what will be a long, dark winter of germs than Teledoc (NYSE: TDOC).
Neuronetics’ flagship product is the NeuroStar Advanced Therapy System. NeuroStar uses transcranial magnetic stimulation (TMS) to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The stock was in the green this week after releasing another denial of fraud allegations levied at the company courtesy of Wolfpack Research back in April. Citing in-person surveys of more than 1,500 people and Chinese credit reports of iQiyi’s VIEs and WFOEs, the short seller claimed that the Chinese entertainment platform overstated its user numbers and inflated its revenues in SEC filings by as much as 261.7% pre-IPO. Further, in 2019, Wolfpack estimated that iQiyi inflated revenue by 27% to 44%. Are they another Luckin Coffee? Maybe. But like Luckin, iQiyi can be both a liar and long-term winner. The SEC launched a probe into iQiyi and its parent company, Baidu (Nasdaq: BIDU).
AXIM(R) Biotechnologies (AXIM) Files Emergency Use Authorization With the FDA for First--in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies